Life Sciences

  • February 24, 2026

    Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit

    Two former Mallinckrodt executives have escaped the only remaining claims they faced in an investor suit tied to the company's 2023 bankruptcy and share cancellations after a New Jersey federal judge said he made a "clear error" keeping them in the suit last year.

  • February 24, 2026

    6th Circ. Affirms Dismissal Of Sotera Toxic Gas Investor Suit

    The Sixth Circuit on Tuesday affirmed a lower court's dismissal of an investor lawsuit accusing Sotera Health Co. of concealing the carcinogenic nature of a gas used at its sterilization plants, finding Sotera did not make any actionable false or misleading statements to investors.

  • February 24, 2026

    Lindis Decries Erasing $50M Verdict Over Inequitable Conduct

    A Delaware federal judge wrongly overruled Lindis Biotech's $50 million infringement verdict against Amgen by falsely concluding an inventor intended to deceive the patent office during prosecution, the German company has told the Federal Circuit.

  • February 24, 2026

    High Court Won't Stay Dow Corning Breast Implant Fund Row

    The U.S. Supreme Court on Tuesday denied a request to stay a lower court's order permanently wiping out the claims of more than 2,600 Koreans who said they were failed by how the settlement was structured, as they were given notice only in English regarding their claims.

  • February 24, 2026

    Novo Nordisk Wants Expert Cut From Hospital Insulin Pen Suit

    Novo Nordisk on Tuesday asked a Connecticut federal judge to remove an expert witness's report and related testimony from an insulin pen contamination lawsuit, hoping a hospital's entire case fails once the expert's opinions are blocked.

  • February 24, 2026

    Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules

    A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.

  • February 24, 2026

    Philips Unit Escapes CPAP Machine Whistleblower Case

    Philips Respironics, a unit of Koninklijke Philips NV, fended off a whistleblower suit alleging it provided kickbacks to CPAP suppliers that bought its products, with a Pennsylvania federal judge ruling that a former Philips manager failed to show that the company willfully engaged in illegal conduct.

  • February 24, 2026

    Biotech Co. Moves To Dismiss LSD Trade Secret Suit

    A biotechnology company accused of having lifted trade secrets regarding clinical trials of potential LSD treatments for psychiatric disorders asked a Delaware federal judge Monday to dismiss or narrow the suit, which it says was brought by a "disgruntled former vendor."

  • February 24, 2026

    Suit Says Ex-Medco CFO Inflated Company's Value Before Sale

    Medical supplier Medline Industries LP has sued the former chief financial officer of United Medco LLC in Florida state court, alleging the executive ran an overbilling scheme that led to an inflated valuation and purchase price for Medco and defrauded a customer of millions of dollars.

  • February 24, 2026

    Headache-Focused Biotech Raises $130M In Series A Round

    Headache disorder-focused biotech Slate Medicines Inc., advised by Cooley LLP, on Tuesday revealed that it wrapped a Series A funding round with $130 million in tow.

  • February 24, 2026

    Life Sciences Group Of The Year: Gibson Dunn

    Gibson Dunn & Crutcher LLP advised 89bio in a complex sale to Roche Holdings that could be worth up to $3.5 billion and won a precedent-setting victory that allowed Sun Pharma to launch an innovative alopecia treatment, earning a spot among the 2025 Law360 Life Sciences Groups of the Year.

  • February 24, 2026

    AstraZeneca Drug Price Challenge Falls Short In Hawaii

    A federal judge in Hawaii temporarily upheld the state's law that prevents drug manufacturers from blocking safety-net hospitals from contracting with an unlimited number of outside pharmacies to dispense discounted prescription drugs under the 340B Drug Discount Program. 

  • February 24, 2026

    Mintz Lands IP Pro From Wilson Sonsini In San Francisco

    Mintz Levin Cohn Ferris Glovsky and Popeo PC. announced Tuesday that it has added a patent litigation attorney who was at Wilson Sonsini Goodrich & Rosati PC for more than two decades to bolster its intellectual property division.

  • February 24, 2026

    8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims

    The Eighth Circuit has affirmed a lower court ruling that tossed a case accusing Iowa Pathology Associates of monopolizing pathology services in central Iowa, finding the rival never explained why doctors can't use labs that are located further away.

  • February 24, 2026

    Judge Tosses Fitch Suit Against Ex-Client In Malpractice Row

    An Illinois federal judge has dismissed a lawsuit brought by intellectual property law firm Fitch Even Tabin & Flannery LLP against the co-founder of a former patent client that accused it of malpractice, saying the firm was improperly seeking a declaration on state law claims without raising a federal question.

  • February 23, 2026

    Bayer Sues J&J Over Alleged False Cancer Drug Claims

    Johnson & Johnson is leaning on a flawed study to advertise its prostate cancer drug as having lower risk of death compared with Bayer's medication, alleged a New York federal lawsuit filed Monday by Bayer, which seeks to immediately halt J&J's advertising campaign and recover damages.

  • February 23, 2026

    DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal

    Sharks and moats were top of mind Monday morning for one judge on the D.C. Circuit, as gene therapy drugmaker Vertex Pharmaceuticals attempted to convince the court that its fertility preservation program does not violate the Anti-Kickback Statute.

  • February 23, 2026

    Zynex Faces Securities Suit Following Arrest Of Former Execs

    After being arrested last month on charges of securities fraud and conspiracy, the former CEO and ex-chief compliance officer of bankrupt medical device maker Zynex have been hit with a securities class action that alleges they and others caused the company to engage in fraudulent billing practices that inflated its stock price and led to investor losses once the truth came to light.

  • February 23, 2026

    Synthego Urges Justices To Reject AI Bait In CRISPR Case

    Synthego Corp. has called for the U.S. Supreme Court to turn away Agilent Technologies Inc.'s appeal of its invalidated CRISPR patents, saying the patent owner is inappropriately leveraging artificial intelligence to make the case sound more pressing than it is.

  • February 23, 2026

    CBP Clears Redesigned Tourniquet Imports After IP Ban

    U.S. Customs and Border Protection has found that a modified version of a tourniquet made by a Chinese company isn't subject to an import ban issued by the U.S. International Trade Commission after finding that earlier imports infringed a patent.

  • February 23, 2026

    Corcept Mischaracterized Drug Approval Odds, Investor Says

    Pharmaceutical company Corcept Therapeutics Inc. faces a proposed investor class action alleging it overstated approval prospects for a Cushing's syndrome drug candidate, hurting investors when its trading prices halved after it disclosed the U.S. Food and Drug Administration wouldn't accept the approval bid.

  • February 23, 2026

    Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit

    A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.

  • February 23, 2026

    Justices Want Natera's Take On CareDx's False Ad Petition

    The U.S. Supreme Court on Monday asked for Natera's position on a petition from rival CareDx asking the high court to review a Third Circuit decision that erased a $45 million jury award stemming from CareDx's false advertising claims.

  • February 23, 2026

    Asthma Biotech Generate Biomedicines Eyes $400M IPO

    Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.

  • February 23, 2026

    Life Sciences Group Of The Year: Ropes & Gray

    Ropes & Gray LLP guided Gilgamesh Pharmaceuticals in a potentially $1.2 billion deal with AbbVie and advised Novo Nordisk in eight licensing and mergers and acquisitions transactions for novel obesity and metabolic disease treatments, earning the firm a spot among the 2025 Law360 Life Sciences Group of the Year.

Expert Analysis

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

  • Ruling On Labor Peace Law Marks Shift For Cannabis Cos.

    Author Photo

    Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.